(19)
(11) EP 3 256 578 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.04.2020 Bulletin 2020/14

(45) Mention of the grant of the patent:
12.02.2020 Bulletin 2020/07

(21) Application number: 16704213.4

(22) Date of filing: 12.02.2016
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
C12N 15/62(2006.01)
C12N 15/867(2006.01)
C07K 14/005(2006.01)
A61K 48/00(2006.01)
C07K 19/00(2006.01)
(86) International application number:
PCT/EP2016/053008
(87) International publication number:
WO 2016/128549 (18.08.2016 Gazette 2016/33)

(54)

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY

POLYPEPTIDE ZUR ENTWICKLUNG CHIMÄRER INTEGRASEPROTEINE UND IHRE VERWENDUNG BEI DER GENTHERAPIE

POLYPEPTIDES POUR L'INGÉNIERIE DE PROTÉINES INTÉGRASES CHIMÉRIQUES ET LEUR UTILISATION EN THÉRAPIE GÉNIQUE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 13.02.2015 EP 15305217

(43) Date of publication of application:
20.12.2017 Bulletin 2017/51

(73) Proprietors:
  • INSERM - Institut National de la Santé et de la Recherche Médicale
    75013 Paris (FR)
  • Centre National de la Recherche Scientifique (C.N.R.S.)
    75016 Paris (FR)
  • Université de Paris
    75006 Paris (FR)
  • Commissariat à l'Energie Atomique et aux Energies Alternatives
    75015 Paris (FR)
  • CNAM Conservatoire National des Arts des Metiers
    75003 Paris (FR)

(72) Inventors:
  • BRIDIER-NAHMIAS, Antoine
    75010 Paris (FR)
  • WERNER, Michel
    91191 Gif-sur-Yvette (FR)
  • LESAGE, Pascale
    75010 Paris (FR)

(74) Representative: Inserm Transfert 
7, rue Watt
75013 Paris
75013 Paris (FR)


(56) References cited: : 
   
  • DEVINE, J. BOEKE: "Invading the yeast nucleus: a nuclear localization signal at the c terminus of ty1 integrase is required for transposition in vivo", MOL CELL BIOL, vol. 18, no. 2, February 1998 (1998-02), pages 1115-1124, XP002743549, cited in the application
  • WILHELM MARCELLE ET AL: "Expression of an active form of recombinant Ty1 reverse transcriptase in Escherichia coli: A fusion protein containing the C-terminal region of the Ty1 integrase linked to the reverse transcriptase-RNase H domain exhibits polymerase and RNase H activities", BIOCHEMICAL JOURNAL, vol. 348, no. 2, 1 June 2000 (2000-06-01), pages 337-342, XP002743550, ISSN: 0264-6021
  • S. P. MOORE; L. A. RINCKEL; D. J. GARFINKEL: "A Ty1 integrase nuclear localization signal required for retrotransposition", MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 2, February 1998 (1998-02), pages 1105-1114, XP002743551, cited in the application
  • MOORE SHARON P ET AL: "Expression and partial purification of enzymatically active recombinant Ty1 integrase in Saccharomyces cerevisiae", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 91, no. 5, 1994, pages 1843-1847, XP002743552, ISSN: 0027-8424
  • MOORE SHARON P ET AL: "Substrate specificity of Ty1 integrase", JOURNAL OF VIROLOGY, vol. 69, no. 8, 1995, pages 4683-4692, XP002743553, ISSN: 0022-538X
  • WILHELM M ET AL: "Role of integrase in reverse transcription of the Saccharomyces cerevisiae retrotransposon Ty1", EUKARYOTIC CELL, vol. 4, no. 6, June 2005 (2005-06), pages 1057-1065, XP002743554,
  • OLIVIER DELELIS ET AL: "Integrase and integration: biochemical activities of HIV-1 integrase", RETROVIROLOGY, vol. 5, 17 December 2008 (2008-12-17), pages 1-13, DOI: doi: 10.1186/1742-4690-5-114
  • ROBERT CRAIGIE: "The molecular biology of HIV integrase", FUTURE VIROL., vol. 7, no. 7, July 2012 (2012-07), pages 679-686, DOI: 10.2217/FVL.12.56
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).